IGF::OT::IGF SBIR Phase II: Topic 338 - Predictive Biomarkers of Adverse Reactions to Prostrate Cancer Radiotherapy

该项目的总体目标是推动临床上有用的多重检测的发展 检测放射敏感性的生物标记物，将识别前列腺癌患者的亚群 放射治疗应禁忌症。这项化验将能够预测发展的风险 放射治疗引起的不良反应--主要是尿路并发症和直肠损伤 前列腺癌。我们的研究已经在多个队列中发现了SNP，这些SNP与 放射治疗引起的不良反应。当前项目的目标是在一个 使用多重SNP分析的独立队列。本项目的技术目标是：(1)评估 一名独立临床患者的临床结局与所有SNP(p-Value&lt；I期10-6)的相关性 SET；(2)扩大原型多重检测的内容，以检测第一阶段发现的相关SNPs；(3) 测试原型分析预测前列腺癌放射治疗不良结果的能力；以及，(4)获得 描述提供者在接收和使用遗传信息时的偏好的定量和定性数据 在放射治疗计划中。

The overall objective of this project is to advance the development of a clinically usefully multiplex assay to detect biomarkers of radio-sensitivity that will identify subsets of prostate cancer patients for which radiotherapy should be contraindicated. This assay will be capable of predicting the risk of developing adverse effects – principally urinary morbidity and rectal injury – resulting from radiotherapy treatment of prostate cancer. Our studies have identified SNPs in multiple cohorts that are strongly associated with adverse effects resulting from radiotherapy. The goal of the current project is to validate these SNPs in an independent cohort using a multiplex SNP assay. The technical objectives of this project are: (1) Evaluate the clinical outcome associations with all SNPs (p-value < 10-6 in Phase I) in an independent clinical patient set; (2) Expand the content of prototype multiplex assay to detect relevant SNPs discovered in Phase I; (3) Test the ability of the prototype assay to predict adverse outcomes to prostate radiotherapy; and, (4) Obtain quantitative and qualtitative data describing provider preferences for receiving and using genetic information in radiotherapy treatment planning.